Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.

HIV infection is not cleared by antiretroviral drugs due to the presence of latently infected cells that are not eliminated with current therapies and persist in the blood and organs of infected patients. New compounds to activate these latent reservoirs have been evaluated so that, along with HAART...

Full description

Bibliographic Details
Main Authors: Celina M Abreu, Sarah L Price, Erin N Shirk, Rodrigo D Cunha, Luiz F Pianowski, Janice E Clements, Amilcar Tanuri, Lucio Gama
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4020785?pdf=render
_version_ 1818012909296418816
author Celina M Abreu
Sarah L Price
Erin N Shirk
Rodrigo D Cunha
Luiz F Pianowski
Janice E Clements
Amilcar Tanuri
Lucio Gama
author_facet Celina M Abreu
Sarah L Price
Erin N Shirk
Rodrigo D Cunha
Luiz F Pianowski
Janice E Clements
Amilcar Tanuri
Lucio Gama
author_sort Celina M Abreu
collection DOAJ
description HIV infection is not cleared by antiretroviral drugs due to the presence of latently infected cells that are not eliminated with current therapies and persist in the blood and organs of infected patients. New compounds to activate these latent reservoirs have been evaluated so that, along with HAART, they can be used to activate latent virus and eliminate the latently infected cells resulting in eradication of viral infection. Here we describe three novel diterpenes isolated from the sap of Euphorbia tirucalli, a tropical shrub. These molecules, identified as ingenols, were modified at carbon 3 and termed ingenol synthetic derivatives (ISD). They activated the HIV-LTR in reporter cell lines and human PBMCs with latent virus in concentrations as low as 10 nM. ISDs were also able to inhibit the replication of HIV-1 subtype B and C in MT-4 cells and human PBMCs at concentrations of EC50 0.02 and 0.09 µM respectively, which are comparable to the EC50 of some antiretroviral currently used in AIDS treatment. Control of viral replication may be caused by downregulation of surface CD4, CCR5 and CXCR4 observed after ISD treatment in vitro. These compounds appear to be less cytotoxic than other diterpenes such as PMA and prostratin, with effective dose versus toxic dose TI>400. Although the mechanisms of action of the three ISDs are primarily attributed to the PKC pathway, downregulation of surface receptors and stimulation of the viral LTR might be differentially modulated by different PKC isoforms.
first_indexed 2024-04-14T06:26:41Z
format Article
id doaj.art-1507cea679ca41d098107ae84e874c04
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-14T06:26:41Z
publishDate 2014-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-1507cea679ca41d098107ae84e874c042022-12-22T02:07:47ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0195e9725710.1371/journal.pone.0097257Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.Celina M AbreuSarah L PriceErin N ShirkRodrigo D CunhaLuiz F PianowskiJanice E ClementsAmilcar TanuriLucio GamaHIV infection is not cleared by antiretroviral drugs due to the presence of latently infected cells that are not eliminated with current therapies and persist in the blood and organs of infected patients. New compounds to activate these latent reservoirs have been evaluated so that, along with HAART, they can be used to activate latent virus and eliminate the latently infected cells resulting in eradication of viral infection. Here we describe three novel diterpenes isolated from the sap of Euphorbia tirucalli, a tropical shrub. These molecules, identified as ingenols, were modified at carbon 3 and termed ingenol synthetic derivatives (ISD). They activated the HIV-LTR in reporter cell lines and human PBMCs with latent virus in concentrations as low as 10 nM. ISDs were also able to inhibit the replication of HIV-1 subtype B and C in MT-4 cells and human PBMCs at concentrations of EC50 0.02 and 0.09 µM respectively, which are comparable to the EC50 of some antiretroviral currently used in AIDS treatment. Control of viral replication may be caused by downregulation of surface CD4, CCR5 and CXCR4 observed after ISD treatment in vitro. These compounds appear to be less cytotoxic than other diterpenes such as PMA and prostratin, with effective dose versus toxic dose TI>400. Although the mechanisms of action of the three ISDs are primarily attributed to the PKC pathway, downregulation of surface receptors and stimulation of the viral LTR might be differentially modulated by different PKC isoforms.http://europepmc.org/articles/PMC4020785?pdf=render
spellingShingle Celina M Abreu
Sarah L Price
Erin N Shirk
Rodrigo D Cunha
Luiz F Pianowski
Janice E Clements
Amilcar Tanuri
Lucio Gama
Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.
PLoS ONE
title Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.
title_full Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.
title_fullStr Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.
title_full_unstemmed Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.
title_short Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.
title_sort dual role of novel ingenol derivatives from euphorbia tirucalli in hiv replication inhibition of de novo infection and activation of viral ltr
url http://europepmc.org/articles/PMC4020785?pdf=render
work_keys_str_mv AT celinamabreu dualroleofnovelingenolderivativesfromeuphorbiatirucalliinhivreplicationinhibitionofdenovoinfectionandactivationofviralltr
AT sarahlprice dualroleofnovelingenolderivativesfromeuphorbiatirucalliinhivreplicationinhibitionofdenovoinfectionandactivationofviralltr
AT erinnshirk dualroleofnovelingenolderivativesfromeuphorbiatirucalliinhivreplicationinhibitionofdenovoinfectionandactivationofviralltr
AT rodrigodcunha dualroleofnovelingenolderivativesfromeuphorbiatirucalliinhivreplicationinhibitionofdenovoinfectionandactivationofviralltr
AT luizfpianowski dualroleofnovelingenolderivativesfromeuphorbiatirucalliinhivreplicationinhibitionofdenovoinfectionandactivationofviralltr
AT janiceeclements dualroleofnovelingenolderivativesfromeuphorbiatirucalliinhivreplicationinhibitionofdenovoinfectionandactivationofviralltr
AT amilcartanuri dualroleofnovelingenolderivativesfromeuphorbiatirucalliinhivreplicationinhibitionofdenovoinfectionandactivationofviralltr
AT luciogama dualroleofnovelingenolderivativesfromeuphorbiatirucalliinhivreplicationinhibitionofdenovoinfectionandactivationofviralltr